Evaluating method for relative pharmacological actions of combinations of immune checkpoint inhibitors and anticancer drugs as combination drugs compared with pharmacological actions of immune checkpoint inhibitors alone, calculating method, evaluating apparatus, calculating apparatus, evaluating program, calculating program, recording medium, evaluating system, and terminal apparatus

A calculating method comprising:

• a calculating step of calculating a value of a formula for evaluating a relative pharmacological action of a combination of an immune checkpoint inhibitor and an anticancer drug as a combination drug compared with a pharmacological action of an immune checkpoint inhibitor alone in the absence of use of an anticancer drug as a combination drug and a value of the formula in the presence of the use, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA in blood of a subject to be evaluated, and (ii) the formula including an explanatory variable to be substituted with the concentration value and an explanatory variable on the presence or absence of the use.

An evaluating apparatus comprising a control unit, wherein the control unit includes:

• an evaluating unit that evaluates a relative pharmacological action of a combination of an immune checkpoint inhibitor and an anticancer drug as a combination drug compared with a pharmacological action of an immune checkpoint inhibitor alone in a subject to be evaluated, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA in blood of the subject to be evaluated, or (ii) a value of a formula in the absence of use of an anticancer drug as a combination drug and a value of the formula in the presence of the use that are calculated using the concentration value and the formula including an explanatory variable to be substituted with the concentration value and an explanatory variable on the presence or absence of the use.

A calculating apparatus comprising a control unit, wherein the control unit includes:

• a calculating unit that calculates a value of a formula for evaluating a relative pharmacological action of a combination of an immune checkpoint inhibitor and an anticancer drug as a combination drug compared with a pharmacological action of an immune checkpoint inhibitor alone in the absence of use of an anticancer drug as a combination drug and a value of the formula in the presence of the use, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA in blood of a subject to be evaluated, and (ii) the formula including an explanatory variable to be substituted with the concentration value and an explanatory variable on the presence or absence of the use.

An evaluating program for causing an information processing apparatus including a control unit to perform an evaluating method,

• wherein the evaluating method includes:
• an evaluating step of evaluating a relative pharmacological action of a combination of an immune checkpoint inhibitor and an anticancer drug as a combination drug compared with a pharmacological action of an immune checkpoint inhibitor alone in a subject to be evaluated, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA in blood of the subject to be evaluated, or (ii) a value of a formula in the absence of use of an anticancer drug as a combination drug and a value of the formula in the presence of the use that are calculated using the concentration value and the formula including an explanatory variable to be substituted with the concentration value and an explanatory variable on the presence or absence of the use.

A calculating program for causing an information processing apparatus including a control unit to perform a calculating method,

• wherein the calculating method includes:
• a calculating step of calculating a value of a formula for evaluating a relative pharmacological action of a combination of an immune checkpoint inhibitor and an anticancer drug as a combination drug compared with a pharmacological action of an immune checkpoint inhibitor alone in the absence of use of an anticancer drug as a combination drug and a value of the formula in the presence of the use, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA in blood of a subject to be evaluated, and (ii) the formula including an explanatory variable to be substituted with the concentration value and an explanatory variable on the presence or absence of the use.

A terminal apparatus comprising a control unit, wherein the control unit includes:

• a result obtaining unit that obtains an evaluation result on a relative pharmacological action of a combination of an immune checkpoint inhibitor and an anticancer drug as a combination drug compared with a pharmacological action of an immune checkpoint inhibitor alone,
• wherein the evaluation result is a result of evaluating the relative pharmacological action of the combination compared with a pharmacological action of an immune checkpoint inhibitor alone in a subject to be evaluated, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA in blood of the subject to be evaluated, or (ii) a value of a formula in the absence of use of an anticancer drug as a combination drug and a value of the formula in the presence of the use that are calculated using the concentration value and the formula including an explanatory variable to be substituted with the concentration value and an explanatory variable on the presence or absence of the use.